Ibutamoren is a compound studied for its potential effects on growth hormone activity, and many people encounter it while researching options for muscle wasting, growth disorders, or metabolic conditions. Current research spans several patient populations and disease areas, though findings vary by trial and stage of development.
Key takeaways
- Eight clinical trials have registered ibutamoren as a study compound across different conditions.
- A phase 3 trial (LUM-201) is currently recruiting children with growth hormone deficiency.
- A completed phase 2 study examined ibutamoren's effects on nonalcoholic fatty liver disease.
- A phase 2 trial evaluating ibutamoren for sarcopenia in post-hip fracture patients was terminated before completion.
- The compound has a molecular weight of about 528.7 g/mol (PubChem CID 178024).
What the evidence shows
Clinicaltrials.gov lists eight registered trials involving ibutamoren, reflecting interest across pediatric, metabolic, and musculoskeletal research areas. One notable phase 3 trial is recruiting children with growth hormone deficiency to assess a related formulation. A separate phase 2 trial, now completed, investigated whether ibutamoren affects nonalcoholic fatty liver disease. A phase 2 study looking at sarcopenia following hip fracture was terminated before reaching its conclusions, illustrating that not all research in this area has been completed as planned.